KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest Expenses: 2017-2025

Historic Interest Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $2.8 million.

  • Aquestive Therapeutics' Interest Expenses fell 0.04% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 4.76%. This contributed to the annual value of $11.1 million for FY2024, which is 75.51% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Interest Expenses stood at $2.8 million for Q3 2025, which was down 0.07% from $2.8 million recorded in Q2 2025.
  • Aquestive Therapeutics' Interest Expenses' 5-year high stood at $2.8 million during Q3 2021, with a 5-year trough of $1.3 million in Q3 2023.
  • For the 3-year period, Aquestive Therapeutics' Interest Expenses averaged around $2.3 million, with its median value being $2.8 million (2024).
  • As far as peak fluctuations go, Aquestive Therapeutics' Interest Expenses plummeted by 41.40% in 2022, and later skyrocketed by 121.34% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Interest Expenses (MRQ) stood at $1.7 million in 2021, then dropped by 5.39% to $1.6 million in 2022, then soared by 37.76% to $2.3 million in 2023, then grew by 22.26% to $2.8 million in 2024, then dropped by 0.00% to $2.8 million in 2025.
  • Its Interest Expenses stands at $2.8 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.8 million for Q1 2025.